Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. patent 12,217,863 by the USPTO for its medical devices with circuitry for capturing and processing physiological signals. The patent protects the company's proprietary technology for real-time physiological monitoring across various applications including heart mapping, arterial mapping, and nervous system monitoring.
The company's innovative platform features a catheter-based microchip sensing array antenna that can detect neural signals with up to 3,000 times greater sensitivity than current technologies. Combined with proprietary RF ablation technology, it enables precise targeting and elimination of overactive nerves.
Autonomix plans to submit an IDE and begin U.S. clinical trials in 2025 to commercialize their Sensing and RF Ablation System for treating pancreatic cancer pain. The company's patent portfolio now includes over 80 issued patents and 40 pending applications.
Autonomix Medical (NASDAQ: AMIX) ha ricevuto il brevetto statunitense 12,217,863 dall'USPTO per i suoi dispositivi medici dotati di circuiti per la cattura e l'elaborazione di segnali fisiologici. Il brevetto protegge la tecnologia proprietaria dell'azienda per il monitoraggio fisiologico in tempo reale in diverse applicazioni, tra cui la mappatura cardiaca, la mappatura arteriosa e il monitoraggio del sistema nervoso.
La piattaforma innovativa dell'azienda presenta un antenna a matrice di microchip basata su catetere che può rilevare segnali neurali con una sensibilità fino a 3.000 volte superiore rispetto alle tecnologie attuali. Combinata con la tecnologia proprietaria di ablazione RF, consente un targeting preciso e l'eliminazione di nervi iperattivi.
Autonomix prevede di presentare un IDE e avviare studi clinici negli Stati Uniti nel 2025 per commercializzare il loro Sistema di Sensing e Ablazione RF per il trattamento del dolore causato dal cancro pancreatico. Il portafoglio brevetti dell'azienda include ora oltre 80 brevetti concessi e 40 domande in sospeso.
Autonomix Medical (NASDAQ: AMIX) ha recibido la patente estadounidense 12,217,863 de la USPTO para sus dispositivos médicos con circuitos para capturar y procesar señales fisiológicas. La patente protege la tecnología propietaria de la empresa para el monitoreo fisiológico en tiempo real en diversas aplicaciones, incluyendo mapeo cardíaco, mapeo arterial y monitoreo del sistema nervioso.
La innovadora plataforma de la empresa cuenta con una antena de matriz de microchip basada en catéter que puede detectar señales neuronales con una sensibilidad de hasta 3,000 veces mayor que las tecnologías actuales. Combinada con la tecnología propietaria de ablación RF, permite una localización precisa y eliminación de nervios hiperactivos.
Autonomix planea presentar un IDE y comenzar ensayos clínicos en EE. UU. en 2025 para comercializar su Sistema de Sensing y Ablación RF para tratar el dolor del cáncer de páncreas. El portafolio de patentes de la empresa ahora incluye más de 80 patentes otorgadas y 40 solicitudes pendientes.
Autonomix Medical (NASDAQ: AMIX)는 USPTO로부터 생리학적 신호를 캡처하고 처리하기 위한 회로가 있는 의료 기기에 대한 미국 특허 12,217,863을 받았습니다. 이 특허는 심장 매핑, 동맥 매핑 및 신경계 모니터링을 포함한 다양한 응용 프로그램에서 실시간 생리학적 모니터링을 위한 회사의 독점 기술을 보호합니다.
회사의 혁신적인 플랫폼은 카테터 기반의 마이크로칩 센싱 배열 안테나를 특징으로 하며, 현재 기술보다 3,000배 더 높은 감도로 신경 신호를 감지할 수 있습니다. 독점 RF 절제 기술과 결합하여 과도하게 활성화된 신경을 정밀하게 표적하고 제거할 수 있습니다.
Autonomix는 2025년에 IDE를 제출하고 미국에서 임상 시험을 시작할 계획입니다 이 시스템을 상용화하기 위해 췌장암 통증을 치료하는 Sensing 및 RF Ablation System을 개발하고 있습니다. 회사의 특허 포트폴리오는 현재 80개 이상의 특허와 40개의 출원 중인 신청서를 포함하고 있습니다.
Autonomix Medical (NASDAQ: AMIX) a reçu le brevet américain 12,217,863 de l'USPTO pour ses dispositifs médicaux dotés de circuits pour la capture et le traitement des signaux physiologiques. Le brevet protège la technologie propriétaire de l'entreprise pour le suivi physiologique en temps réel dans diverses applications, y compris la cartographie cardiaque, la cartographie artérielle et le suivi du système nerveux.
La plateforme innovante de l'entreprise dispose d'une antenne à matrice de microchip basée sur un cathéter capable de détecter des signaux neuronaux avec une sensibilité allant jusqu'à 3 000 fois supérieure à celle des technologies actuelles. Associée à une technologie d'ablation RF propriétaire, elle permet un ciblage précis et l'élimination des nerfs hyperactifs.
Autonomix prévoit de soumettre un IDE et de commencer des essais cliniques aux États-Unis en 2025 pour commercialiser leur système de détection et d'ablation RF pour traiter la douleur liée au cancer du pancréas. Le portefeuille de brevets de l'entreprise comprend désormais plus de 80 brevets accordés et 40 demandes en attente.
Autonomix Medical (NASDAQ: AMIX) hat vom USPTO das US-Patent 12,217,863 für seine medizinischen Geräte mit Schaltungen zur Erfassung und Verarbeitung physiologischer Signale erhalten. Das Patent schützt die proprietäre Technologie des Unternehmens für die Echtzeit-Überwachung physiologischer Daten in verschiedenen Anwendungen, einschließlich Herzabbildung, Arterienabbildung und Überwachung des Nervensystems.
Die innovative Plattform des Unternehmens verfügt über eine katheterbasierte Mikrochipsensor-Antennenanordnung, die neuronale Signale mit einer bis zu 3.000-fachen Empfindlichkeit im Vergleich zu aktuellen Technologien erkennen kann. In Kombination mit der proprietären RF-Ablationstechnologie ermöglicht sie eine präzise Zielverfolgung und Eliminierung überaktiver Nerven.
Autonomix plant, 2025 einen IDE einzureichen und klinische Studien in den USA zu beginnen, um ihr Sensing- und RF-Ablationssystem zur Behandlung von Schmerzen bei Bauchspeicheldrüsenkrebs zu kommerzialisieren. Das Patentportfolio des Unternehmens umfasst nun über 80 erteilte Patente und 40 anhängige Anträge.
- Secured new U.S. patent protection for core technology
- Technology demonstrates 3,000x greater sensitivity in neural signal detection
- Extensive IP portfolio with 80+ issued patents
- Early clinical results showing promise in pancreatic cancer pain reduction
- Multiple potential commercial applications across different medical fields
- Product still requires FDA approval with clinical trials not yet started
- Commercialization timeline extends into 2025 and beyond
- Faces competition from established pain management treatments
Insights
Autonomix Medical's newly granted U.S. patent (12,217,863) strengthens the company's intellectual property foundation for its neural sensing and processing technology. This patent specifically protects the company's methods for collecting and processing sensing data for real-time physiological monitoring across multiple applications including heart mapping and neural monitoring.
With this addition, Autonomix has built a substantial IP portfolio of over 80 issued patents and 40 pending applications, creating significant barriers to entry in their specialized field. For a micro-cap company with a
The company's planned IDE submission and clinical trials in 2025 for pancreatic cancer pain treatment establishes a concrete development pathway, though investors should recognize that revenue remains years away. The technology's potential applications across multiple high-value indications including cancer pain management and hypertension suggests substantial addressable markets if successfully developed.
While patent grants don't guarantee commercial success, this intellectual property protection is strategically important as the company progresses toward clinical validation of its technology that reportedly offers 3,000 times greater sensitivity than existing alternatives.
The technological capabilities protected in Autonomix's newly patented system represent a potentially significant advancement in neural intervention precision. Current technologies for neural signal detection lack the sensitivity necessary for many therapeutic applications, particularly in areas with complex innervation.
The company's catheter-based microchip sensing array technology claims 3,000-fold greater sensitivity in neural signal detection compared to existing technologies. This enhanced precision could fundamentally change how physicians target overactive nerves in multiple conditions.
Particularly noteworthy is the integrated approach combining both sensing and ablation capabilities in a single platform. This enables a "sense, treat, and verify" methodology that could significantly improve procedural outcomes compared to current less-targeted approaches.
The initial focus on pancreatic cancer pain addresses a significant unmet need. Pancreatic cancer patients often suffer from severe pain poorly managed by current options, which primarily rely on opioids with their associated limitations and side effects, or invasive ethanol injections.
The expansion potential into hypertension and broader cardiovascular applications represents substantial market opportunities beyond oncology. The ability to precisely target specific neural pathways involved in blood pressure regulation could potentially address a condition affecting hundreds of millions worldwide that often requires lifetime medication.
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications
Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications
THE WOODLANDS, TX, March 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. patent 12,217,863 (‘863 patent) titled, Medical Devices with Circuitry for Capturing and Processing Physiological Signals. The issued ‘863 patent gives Autonomix protection of proprietary technology used to collect and process sensing data for real-time physiological monitoring with broad application use that includes, e.g., heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring and implant, robotic and wearable precision applications.
“We are pleased to strengthen our patent protection for this potential groundbreaking technology. The continued positive data on its application, efficacy, and safety reinforce our confidence in its potential. We remain committed to advancing this innovation to address critical areas of unmet medical need. To date, our early clinical results have been highly encouraging for reducing pancreatic cancer pain. Beyond cancer pain, our technology holds promise for a broad range of conditions where nerve activity plays a key role, including hypertension within the cardiovascular space,” commented Brad Hauser, CEO of Autonomix.
Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.
The Company expects to submit an IDE and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.
For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer, to submit and receive approval of an IDE, and to file a De Novo application. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What is the significance of Autonomix Medical's (AMIX) new U.S. patent 12,217,863?
How much more sensitive is AMIX's neural signal detection technology compared to existing solutions?
When will AMIX begin clinical trials for their pancreatic cancer pain treatment system?
What are the potential applications of AMIX's sensing and ablation technology?
How many patents does Autonomix Medical currently hold in their portfolio?
